In vivo characterization of 5-HT7 modulators in RAT models of opioid use disorder - opioid analgesics (e.g. fentanyl, morphine, oxycodone) are widely used to treat and manage moderate to severe…
Active Grant Awarded
- Award ID
- R43DA064569
- Recipient
-
Praeventix LLC UEI NLSMGTKWQR16
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $355,190
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 49% complete
- Place of performance
- Exton, PA 19341, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse awarded Praeventix LLC a $355,190 grant on May 19, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279), Grant R43DA064569. The recipient will conduct in vivo characterization of 5-HT7 modulators in rat models of opioid use disorder. The source's narrative builds on a series of drug-like 5-HT7 antagonists, led by compound PRA078, which produced a statistically significant reduction in cue-induced reinstatement in a rat cocaine use disorder model. The full $355,190 is obligated. The period runs from the May 19, 2026 award date to an ultimate completion date of May 31, 2027. Work is performed at Exton, PA 19341, USA. The source identifies no sub-recipients for this award. The program supports basic, clinical, translational, and implementation research on drug use, misuse, addiction, and overdose, and the award is classified as a grant.
Description
In vivo characterization of 5-HT7 modulators in RAT models of opioid use disorder - opioid analgesics (e.g. fentanyl, morphine, oxycodone) are widely used to treat and manage moderate to severe acute pain resulting from trauma or surgery as well as some types of chronic pain. IT is well established that these drugs exert their influence through activation of the Μ-opioid receptor. Unfortunately, opioids are also highly addictive and physical dependence on these drugs can be established after as little as a few days of sustained use. Between 1999 and 2020, >565,000 people died from an opioid involved overdose, and in 2022 nearly 70% of drug overdose deaths (~74K of ~108K) involved synthetic opioids, primarily fentanyl. In addition, according to the national survey on drug use and health, ~2.7 million people were suffering with opioid use disorder (OUD) in 2020 and the economic impact of the opioid crisis in the US was ~$1.5 trillion. Although treatments such as methadone (DOLOPHINE), buprenorphine (SUBUTEX) and naltrexone (REVIA) are available, only 24% of OUD patients received treatment in 2022 and the risk of relapse is high. The danger of long-term opioid use extends beyond the risk of overdose death, as patient experiencing OUD are at increased risk for a wide range of additional negative health consequences. There is a clear, present, and persistent need to develop novel therapies for OUD. Studies demonstrate that antagonism of the 5-HT7 receptor can regulate key dopamine pathways involved in substance use disorder and improve cognitive flexibility and memory. These improvements are especially noted in assays with links to negative states such as psychosis, depression, stress, and withdrawal. We have identified a series of novel, drug-like 5-HT7 antagonists that include a lead compound, PRA078, which produces a statistically significant reduction in a CUE-induced reinstatement RAT model of cocaine use disorder. In this program, we will determine the impact of our lead compound on RAT models of opioid use disorder. This data will support our continued advancement of this compound into pre-clinical IND enabling studies as a treatment for opioid use disorder.
Quick answers
Who received award R43DA064569?
R43DA064569 was awarded to Praeventix LLC by National Institute on Drug Abuse (National Institutes of Health) on May 19, 2026.
How much is award R43DA064569 worth?
$355,190 has been obligated on R43DA064569.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award